OncoMark are actively involved in collaboration R&D projects focused on the identification of biomarkers in cancer progression and drug toxicity. Specifically, OncoMark participates in six EU FP7 research programmes. These include three Marie Curie Industry Academia Partners and Partnerships programmes: 'Target Melanoma', 'Angiotox' and 'FASTPATH' and the Cooperation Health programmes 'RATHER' and 'AngioPredict'. The 'APO-DECIDE' project is also funded as part of the European Framework Programme 7 collaborative project for small or medium scale focused research projects.
Please see below the overview PDF brochures for each of these projects.